Co-Authors
This is a "connection" page, showing publications co-authored by ROBERT C BAST JR and GORDON B MILLS.
Connection Strength
4.064
-
Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. Cancer Discov. 2012 Jan; 2(1):16-8.
Score: 0.413
-
Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol. 2010 Aug 01; 28(22):3545-8.
Score: 0.371
-
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009 Jun; 9(6):415-28.
Score: 0.345
-
General keynote: molecular therapeutics and pharmocogenomics. Gynecol Oncol. 2003 Jan; 88(1 Pt 2):S84-7; discussion S93-6.
Score: 0.221
-
Early detection of ovarian cancer: promise and reality. Cancer Treat Res. 2002; 107:61-97.
Score: 0.207
-
Should therapy of ovarian cancer patients be individualized based on underlying genetic defects? Clin Cancer Res. 1999 Sep; 5(9):2286-8.
Score: 0.176
-
CA 125: the past and the future. Int J Biol Markers. 1998 Oct-Dec; 13(4):179-87.
Score: 0.165
-
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53.
Score: 0.105
-
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23; 11(10):719-25.
Score: 0.101
-
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 2008 Dec; 118(12):3917-29.
Score: 0.083
-
Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res. 2007; 174:91-100.
Score: 0.073
-
10th Biennial Helene Harris Memorial Trust meeting. Cancer Res. 2006 Mar 15; 66(6):2904-6.
Score: 0.069
-
Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem. 2005 Jan 21; 280(3):2092-104.
Score: 0.063
-
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004 May 15; 10(10):3291-300.
Score: 0.061
-
A genetically defined model for human ovarian cancer. Cancer Res. 2004 Mar 01; 64(5):1655-63.
Score: 0.060
-
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004 Mar 05; 279(10):9653-61.
Score: 0.059
-
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol. 2003 Oct; 30(5 Suppl 16):93-104.
Score: 0.058
-
Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer. 2003 Sep; 39(13):1818-27.
Score: 0.058
-
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3534-45.
Score: 0.058
-
ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene. 2003 May 15; 22(19):2897-909.
Score: 0.057
-
Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene. 2003 Jan 30; 22(4):484-97.
Score: 0.056
-
Specific keynote: molecular therapeutics in ovarian cancer. Gynecol Oncol. 2003 Jan; 88(1 Pt 2):S88-92; discussion S93-6.
Score: 0.055
-
Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. Oncogene. 2001 Dec 13; 20(57):8258-69.
Score: 0.051
-
Translational research--traffic on the bridge. Biomed Pharmacother. 2001 Nov; 55(9-10):565-71.
Score: 0.051
-
Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst. 2001 Oct 03; 93(19):1437-9.
Score: 0.051
-
Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene. 2000 Dec 14; 19(54):6277-85.
Score: 0.048
-
Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J. 2000 Dec 01; 352 Pt 2:475-82.
Score: 0.048
-
Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J. 2000 Nov 15; 352 Pt 1:135-43.
Score: 0.048
-
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A. 2000 Oct 24; 97(22):11960-5.
Score: 0.048
-
Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Res. 2000 Jul 01; 60(13):3522-31.
Score: 0.047
-
Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res. 2000 Jan; 6(1):260-70.
Score: 0.045
-
Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res. 1999 Dec; 5(12):4308-18.
Score: 0.045
-
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene. 1999 Nov 18; 18(48):6635-40.
Score: 0.045
-
The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res. 1999 Nov; 5(11):3653-60.
Score: 0.044
-
Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res. 1999 Nov; 5(11):3704-10.
Score: 0.044
-
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A. 1999 Jan 05; 96(1):214-9.
Score: 0.042
-
Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene. 1998 Jan 08; 16(1):1-8.
Score: 0.039
-
Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. Acta Oncol. 1998; 37(7-8):629-40.
Score: 0.039
-
Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res. 1997 Sep; 3(9):1629-34.
Score: 0.038
-
Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. J Biol Chem. 1997 May 23; 272(21):13683-9.
Score: 0.038
-
Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer. 1995 Nov 01; 76(9):1615-20.
Score: 0.034
-
The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. Int J Cancer. 1994 Oct 15; 59(2):242-7.
Score: 0.031
-
Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer. 1994 Jul 01; 74(1):93-9.
Score: 0.031
-
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle. 2010 Jan 01; 9(1):140-6.
Score: 0.022
-
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008 Sep; 47(9):701-6.
Score: 0.021
-
Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol. 2008 Mar; 108(3):652-7.
Score: 0.020
-
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A. 2006 Oct 31; 103(44):16472-7.
Score: 0.018
-
Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis. 2007 Jan; 28(1):174-82.
Score: 0.018
-
Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006 Mar 01; 66(5):2740-8.
Score: 0.017
-
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005 Sep 01; 11(17):6116-26.
Score: 0.017
-
A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res. 2005 Aug 01; 65(15):6701-10.
Score: 0.017
-
Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol. 2003 Jul; 90(1):44-50.
Score: 0.014
-
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol. 2003 Jan; 88(1):73-9.
Score: 0.014
-
Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 2001 Aug 01; 61(15):5895-904.
Score: 0.013
-
Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res. 1999 Dec; 5(12):4053-8.
Score: 0.011
-
Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol. 1999 Nov; 75(2):261-6.
Score: 0.011
-
Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res. 1999 Mar; 5(3):655-63.
Score: 0.011
-
Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res. 1998 May 15; 58(10):2253-9.
Score: 0.010
-
Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene. 1997 Nov 20; 15(21):2589-96.
Score: 0.010